PUBLISHER: Grand View Research | PRODUCT CODE: 1986325
PUBLISHER: Grand View Research | PRODUCT CODE: 1986325
The global animal drug compounding market size was estimated at USD 1.68 billion in 2025 and is projected to reach USD 3.25 billion by 2033, growing at a CAGR of 8.52% from 2026 to 2033. The market is advancing due to increasing demand for personalized veterinary therapies, shortages and discontinuation of commercial veterinary drugs and rising pet ownership and veterinary spending.
Rising complexity in veterinary care is driving demand for personalized drug formulations customized to diverse animal needs. The standardized medications often fail to provide precise dosing, suitable delivery routes, or acceptable palatability. Besides this, compounding enables veterinarians to adjust strength, formulation, excipients, and flavor, improving compliance and therapeutic outcomes. In addition, personalized therapies are particularly important for small mammals, geriatric animals, and chronic cases requiring long-term treatment. In addition, compounded drugs can be prepared as flavored suspensions, micro-dosed capsules, or transdermal gels to match species-specific requirements.
In addition, ongoing supply disruptions and discontinuation of veterinary drugs are increasing reliance on compounding to maintain continuity of care. The market withdrawals due to limited demand, manufacturing challenges, or regulatory changes often leave treatment gaps, particularly for niche species and specialized conditions. Besides this, veterinary compounding enables pharmacists to recreate discontinued medications or prepare therapeutic alternatives, ensuring uninterrupted access to essential therapies. This is especially critical for chronic, geriatric, and specialty treatments with limited commercial substitutes. In addition, growing supply chain volatility, raw material shortages, and shifting manufacturing priorities have made compounding an indispensable support system, particularly for rural veterinary practices and specialty clinics facing constrained drug availability.
Furthermore, rising global pet ownership, particularly among urban and middle-income households, is driving increased demand for veterinary care and personalized treatments. Besides this, pets are regarded as family members, encouraging higher spending on diagnostics, preventive care, and specialized therapies. Thus, compounded medications provide flexible, veterinarian-directed solutions when standard commercial products are unsuitable, especially for chronic diseases, pain management, and geriatric conditions. In addition, veterinary spending continues to grow across North America, Western Europe, and Asia Pacific, supported by rising disposable incomes and expanding pet insurance coverage. In the U.S., widespread pet ownership across multiple species further strengthens demand for customized, species-specific compounded formulations.
Global Animal Drug Compounding Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global animal drug compounding market report based on product, animal, route of administration, dosage form, and region: